Navigation Links
Intermountain Medical Center Uses SynCardia Total Artificial Heart to Bridge 31-Year-Old Father to a Heart Transplant
Date:3/21/2013

TUCSON, Ariz., March 21, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Andrew Weaver , a 31-year-old husband and father of one who arrived at Intermountain Medical Center in Salt Lake City in grave condition, has been successfully bridged to a heart transplant with the SynCardia temporary Total Artificial Heart and discharged home.

(Photo: http://photos.prnewswire.com/prnh/20130321/LA81060)

"We had several concerns when Andrew first came to us," said Dr. Bruce Reid , surgical director of the Intermountain Medical Center Artificial Heart Program. "He had extensive thrombus in the left ventricle and profound biventricular failure. To use an LVAD would've been a very dangerous situation fraught with a high risk of stroke. It was for that reason we felt the best course of action was to replace his heart with the Total Artificial Heart."

Mr. Weaver was born with a congenitally malformed aortic valve, and developed an aneurysm of the ascending aorta. However, these abnormalities were unknown until last February. Over time, his chest pains got increasingly worse. In October, he underwent surgery at a local hospital to have his aorta and aortic valve replaced, but was unable to be weaned from cardiopulmonary bypass. When his heart wouldn't start beating again, he was transferred to Intermountain Medical Center.

"He arrived on ECMO [a machine that takes over the function of the heart and lungs] with an open chest in critical condition," said Dr. Reid. "We kept him on ECMO for a few days hoping that he'd have some cardiac recovery, but he did not. We didn't feel we could bridge him with anything less than a Total Artificial Heart."

Mr. Weaver was implanted with the SynCardia Total Artificial Heart on Oct. 18, 2012. Over the next several months, hospital staff helped him regain his strength and improve his health so he could be listed for a heart transplant. On Jan. 7, he was added to the waiting list, and just five days later, he received his heart transplant. On Jan. 24, Mr. Weaver was discharged from the hospital with his new donor heart. He is currently enjoying life at home with his wife of three years Heather and their 17-month-old daughter Haley and has returned to his job as a supply chain specialist.

"Without the SynCardia Total Artificial Heart, my husband would not have lived, Haley would have grown up without her dad and I would have lost my best friend," said Heather. "Having him home is the best thing in the world!"

About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – http://twitter.com/SynCardia
Connect with SynCardia on LinkedIn - http://www.linkedin.com/company/syncardia-systems-inc.


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Intermountain Healthcare and Myriad Genetics Enter Into Research Collaboration Agreement
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Medical Device Developers - Network at BIOMEDevice Boston Next Week
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
6. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
7. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Essential Medical Dismisses Patent Case against Masimo and Cercacor
10. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
11. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... Israel, May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... technology which enables the functional selection of stem cells, ... for the first quarter ended March 31 st , ... our accomplishments in the first quarter of 2017," said ... quarter, we announced the treatment of the first blood ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased ... separator supplier for CDA members. As part of the amalgam separator endorsement, all CDA ... saving more than $400 off the retail value. This partnership between PureLife and CDA ...
(Date:6/23/2017)... ... 2017 , ... Ulster University, Magee Campus in Northern Ireland is hosting The ... to present to graduate students exciting new and innovative hope research based on iFred’s ... The Health Improvement Service of the Western Health & Social Care Trust (WHSCT) in ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency that offers ... Texas, is announcing the launch of a new charity drive to benefit women in ... United States reveal that an estimated 252, 710 new cases of invasive or high ...
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... June 22, 2017 , ... Groove Ring is excited ... about their high performance silicon wedding bands and all-purpose rings. Whether you’re an athlete, ... silicone rings designed just for you. , From the rock face to the auto ...
Breaking Medicine News(10 mins):